35121-78-9 Usage
Description
Epoprostenol, also known as Prostacyclin, PGI2, Prostaglandin I2, or Prostaglandin X, is a synthetic medication derived from prostaglandins. It is a vasodilator and an inhibitor of platelet aggregation, which makes it useful in various medical applications. Epoprostenol is produced under the brand name Flolan by GlaxoSmithKline.
Uses
Used in Pharmaceutical Industry:
Epoprostenol is used as an inhibitor (platelet) for managing conditions that involve abnormal blood clotting or high blood pressure in the arteries of the lungs (pulmonary arterial hypertension). It helps to prevent blood clot formation and dilates blood vessels, improving blood flow and reducing the workload on the heart.
Used in Cardiovascular Applications:
In the cardiovascular field, Epoprostenol is used as a vasodilator to treat pulmonary arterial hypertension. It works by relaxing the smooth muscle cells in the walls of blood vessels, leading to the widening of the blood vessels and a subsequent decrease in blood pressure.
Used in Hematology:
Epoprostenol is utilized as an antiplatelet agent in the field of hematology, particularly for patients with conditions that increase the risk of blood clot formation, such as sickle cell disease or those undergoing procedures that may cause clotting issues.
Used in Critical Care Medicine:
In critical care medicine, Epoprostenol is used as a therapeutic agent for patients with severe pulmonary hypertension, as it can help to improve oxygenation and reduce the strain on the right side of the heart.
Used in Research and Development:
Epoprostenol is also used in research and development for the study of prostaglandins and their role in various physiological processes, as well as for the development of new medications with similar or improved properties.
Originator
Prostacyclin,ZYF Pharm Chemical
Manufacturing Process
Preparation of prostacyclin:Pig aortas were stripped of adventitia, snap frozen in liquid nitrogen, crushed
into a fine powder, resuspended in 0.05 M Tris buffer (pH 7.5) (1:4, w:v) andhomogenised at high speed in a Polytron (KIMENATIC, LUCERNE,
SWITZERLAND) homogenizer. The homogenate was centrifuged for 15 min
and the resulting supernatant centrifuged again for 5 min. The pellet was
discarded, while the pellet obtained after centrifugation of the supernatant
was resuspended in deionized water and lyophilized. An average yield of 150
mg of aortic microsomal powder (51% protein) per 100 g of aortic tissue was
obtained.
Therapeutic Function
Platelet aggregation inhibitor, Antimetastatic
Check Digit Verification of cas no
The CAS Registry Mumber 35121-78-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,1,2 and 1 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 35121-78:
(7*3)+(6*5)+(5*1)+(4*2)+(3*1)+(2*7)+(1*8)=89
89 % 10 = 9
So 35121-78-9 is a valid CAS Registry Number.
InChI:InChI=1/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17?,18+,19?/m0/s1
35121-78-9Relevant articles and documents
A SHORT WAY TO PROSTACYCLIN
Suzuki, M.,Yanagisawa, A.,Noyori, R.
, p. 1187 - 1188 (1983)
A facile, stereospecific preparation of prostacyclin has been accomplished starting from a 5,6-dehydroprostaglandin F2α derivative.
ANTIHYPERTENSIVE THERAPY
-
, (2009/09/08)
A new use of darusentan is provided in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy with one or more drugs. The composition comprises darusentan in an amount providing a therapeutically effective daily dose; wherein (a) the composition is orally deliverable and/or (b) the daily dose of darusentan is effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures. Further provided is a new use of darusentan in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy, wherein the composition is administered adjunctively with at least one diuretic and at least one antihypertensive drug selected from ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers.
Prodrug derivatives of carboxylic acid drugs
-
, (2008/06/13)
Novel ester derivatives of carboxylic acid medicaments of formula (I), wherein R--COO--represents the acyloxy residue of a carboxylic acid drug or medicament, n is an integrer from 1 to 3, and R1 and R2 are the same or different and are selected from a group consisting of an alkyl, an alkenyl, an aryl, an aralkyl, a cycloalkyl and which group may be unsubstituted or substituted, or R1 and R2 together with the N forms a 4-, 5-, 6- or 7-membered heterocyclic ring, which in addition to the nitrogen atom may contain one or two further heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and which heterocyclic group may be substituted. These compounds are highly biolabile prodrug forms of the corresponding carboxylic acid compounds and are highly susceptible to undergoing enzymatic hydrolysis in vivo whereas they are highly stable in aqueous solution. The novel derivatives are less irritating to mucosa than the parent carboxylic acids and may provide an improved bio-availability of the drugs.
